Skyrizi 75 mg solution for injection in pre-filled syringe

Manufacturer
AbbVie S.r.l(ITALY)

Registraction Number
MAL19126007ACRZ

Content:
Skyrizi 75 mg Solution for Injection in Pre-filled Syringe contains 75 mg of risankizumab per 0.83 ml of solution. Risankizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively targets the interleukin (IL)-23 protein.
Indications:

• Plaque Psoriasis: Used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
• Psoriatic Arthritis: Used for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
• Palmoplantar Pustulosis: Used for the treatment of moderate to severe palmoplantar pustulosis in adults who do not adequately respond or are intolerant to conventional therapy.

• Dosage: The recommended dose is 150 mg administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter. This can be achieved by injecting two 75 mg pre-filled syringes.
• Administration: Inject subcutaneously (under the skin), typically in the abdomen or thigh. Rotate injection sites to prevent complications.
• Precautions: Inform your doctor if you have any allergies, infections, or other health conditions. Follow your doctor's instructions carefully.
• Storage: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or expose to high temperatures.